Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Karl Heinz Heider"'
Autor:
Wolfgang Sommergruber, Martin Schreiber, Christian Stratowa, Karl-Heinz Heider, Ernst Kubista, Sonja Vogl, Gerhard Dekan, Agnes Gruenfelder, Margit Pacher, Peter Steinlein, Herbert Auer, Ulrich Koenig, Stefan Amatschek
With the objective of discovering novel putative intervention sites for anticancer therapy, we compared transcriptional profiles of breast cancer, lung squamous cell cancer (LSCC), lung adenocarcinoma (LAC), and renal cell cancer (RCC). Each of these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54170c6e939727dc42a7a0e35e06c7d6
https://doi.org/10.1158/0008-5472.c.6493622
https://doi.org/10.1158/0008-5472.c.6493622
Autor:
William Blum, Sumithira Vasu, Xiaokui Mo, Rajeswaran Mani, Katherine Walsh, Natarajan Muthusamy, Bhavana Bhatnagar, Donna Bucci, Karl-Heinz Heider, Irene Waizenegger, Alison Walker, Bhavani Gopalakrishnan, Carolyn Cheney, Rebecca B. Klisovic, Bjoern Rueter
Publikováno v:
Oncotarget
Acute myeloid leukemia (AML) is the second most common type of leukemia in adults. Incidence of AML increases with age with a peak incidence at 67 years. Patients older than 60 years have an unfavorable prognosis due to resistance to conventional che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d40bf3c44e97dc686ac8cf8013dd2343
https://doi.org/10.18632/oncotarget.23880
https://doi.org/10.18632/oncotarget.23880
Autor:
Franziska Hessel, Michael Baumann, Kristin Gurtner, Annegret Dörfler, Wolfgang Eicheler, Daniel Zips, Mechthild Krause, Karl-Heinz Heider
Publikováno v:
Radiotherapy and Oncology. 102:444-449
Background and purpose To test whether BIWI 1 (bivatuzumab mertansine), an immunoconjugate of the humanized anti-CD44v6 monoclonal antibody BIWA 4 and the maytansinoid DM1, given simultaneously to fractionated irradiation improves local tumour contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b2193984ea54260729068d165e6de29
https://doi.org/10.1016/j.radonc.2011.10.013
https://doi.org/10.1016/j.radonc.2011.10.013
Autor:
Elinborg Ostermann, Guenther Adolf, Dontscho Kerjaschki, Karl Heinz Heider, Milena Kalat, Christina Puri, Wolfgang Rettig, Pilar Garin-Chesa, Herbert Lamche
Publikováno v:
Clinical Cancer Research. 14:4584-4592
Purpose: Invasion and metastasis of malignant epithelial cells into normal tissues is accompanied by adaptive changes in the mesenchyme-derived supporting stroma of the target organs. Altered gene expression in these nontransformed stromal cells prov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b869fdecb5638bebd0880b3b5bd07e
https://doi.org/10.1158/1078-0432.ccr-07-5211
https://doi.org/10.1158/1078-0432.ccr-07-5211
Autor:
Imaan Baki, Günter Krause, Eva Knödgen, Elisa Göckeritz, Susan Kerwien, Thomas Landwehr, Lars Neumann, Karl-Heinz Heider, Michael Hallek
Publikováno v:
British journal of haematology. 173(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eb0937fa04369a16a19c20040bf7c9c
https://pubmed.ncbi.nlm.nih.gov/26271483
https://pubmed.ncbi.nlm.nih.gov/26271483
Autor:
Agnes Gruenfelder, Peter Steinlein, Margit Pacher, Stefan Amatschek, Wolfgang Sommergruber, Gerhard Dekan, Herbert Auer, Ulrich Koenig, Christian Stratowa, Karl-Heinz Heider, Ernst Kubista, Martin Schreiber, Sonja Vogl
Publikováno v:
Cancer Research. 64:844-856
With the objective of discovering novel putative intervention sites for anticancer therapy, we compared transcriptional profiles of breast cancer, lung squamous cell cancer (LSCC), lung adenocarcinoma (LAC), and renal cell cancer (RCC). Each of these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e746e37b731aa130bf8465ebf1f9b9a3
https://doi.org/10.1158/0008-5472.can-03-2361
https://doi.org/10.1158/0008-5472.can-03-2361
Autor:
Robert P. Bleichrodt, Hartmut Kuthan, Jan C. Roos, Paul van Leeuwen, Karl-Heinz Heider, Frank van Schaijk, Manuel Koppe
Publikováno v:
Cancer Biotherapy & Radiopharmaceuticals, 19, 720-9
Cancer Biotherapy & Radiopharmaceuticals, 19, 6, pp. 720-9
Cancer Biotherapy & Radiopharmaceuticals, 19, 6, pp. 720-9
Contains fulltext : 58950schaijk.pdf (Publisher’s version ) (Closed access) The aim of this prospective study was to evaluate the safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized anti-CD44v6 monoclonal anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6f8273be39f7089f4bdd33ffa4c6638
https://hdl.handle.net/2066/58950
https://hdl.handle.net/2066/58950
Autor:
Walter Fürst, Alexander Dohnal, Wolfgang Sommergruber, Karl-Heinz Heider, Christoph St. Klade, Manfred Ratschek, Günther R. Adolf, Helen Gharwan
Publikováno v:
International Journal of Cancer. 97:217-224
With the objective of discovering novel tumor-associated antigens of the cancer/testis type, we compared the transcriptional profiles of renal cell carcinoma (RCC) and non-tumorous kidney and further screened for genes expressed in RCC and testis, bu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b8628f50b98e533cd3e2e098b4b6f36
https://doi.org/10.1002/ijc.1582
https://doi.org/10.1002/ijc.1582
Autor:
Deborah M Stephens, Kyle A. Beckwith, Priscilla Do, Carolyn Cheney, Xiaokui Mo, Karilyn Larkin, Jeffrey Jones, Farrukh T. Awan, Laura Grosmaire, Randy Jones, Julie DiPaolo, Stacey Tannheimer, Karl-Heinz Heider, John C. Byrd, Natarajan Muthusamy
Publikováno v:
Blood. 128:2767-2767
Background Targeting new antigens in chronic lymphocytic leukemia (CLL) and lymphoma may increase flexibility in the clinic and help circumvent resistance. The tetraspanin CD37 domain mediates transduction of survival and apoptotic signals (Lapalombe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca8864c35987f156901b11d6a759c1a8
https://doi.org/10.1182/blood.v128.22.2767.2767
https://doi.org/10.1182/blood.v128.22.2767.2767
Autor:
Sylvia Brunner, Ernst Wagner, Ralf Kircheis, Wolfgang Zauner, Manfred Ogris, Susanne Schüller, Karl-Heinz Heider
Publikováno v:
The Journal of Gene Medicine. 1:111-120
Background Efficient and target-specific in vivo gene delivery is a major challenge in gene therapy. Compared to cell culture application, in vivo gene delivery faces a variety of additional obstacles such as anatomical size constraints, interactions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3105bb44771c66d729887c82425843d0
https://doi.org/10.1002/(sici)1521-2254(199903/04)1:2<111::aid-jgm22>3.0.co
https://doi.org/10.1002/(sici)1521-2254(199903/04)1:2<111::aid-jgm22>3.0.co